Table 2.

Biologic Agents for the Treatment of Severe Asthma²⁰,²³,²⁶,³⁰,³⁴–³⁹

Treatment (Brand)	Mechanism of Action	Type of Antibody	Approved for Use (y)
Omalizumab (Xolair)	Antibody that creates inert IgE complexes and stops complement activation	Humanized MAB	Yes (2003)
Mepolizumab (Nucala)	Binds directly to IL-5 and prevents eosinophil activation	Humanized MAB	Yes (2015)
Reslizumab (Cinqair)	Binds directly to IL-5 and prevents eosinophil activation	Humanized MAB	Yes (2016)
Dupilumab	Binds to the IL-4Rα subunit of the IL-4 receptor, blocks Th2 activation	Human MAB	No, but received FDA “breakthrough therapy” designation
Fevipiprant	Prostaglandin D2 receptor antagonist, blocks migration of Th2 cells, cytokines, prevents eosinophil activation	N/A	No
Benralizumab	Anti-IL-5 receptor, block eosinophil activation	Humanized MAB	No

Abbreviations: IG, immunoglobulin; IL, interleuken; MAB, monoclonal antibody, Th2, T helper type 2.